Constructs targeting well-defined tumor-associated antigens such as HER2, DLL3, PSMA, CEA, and EGFRvIII have entered advanced clinical trials across a variety of solid tumor types, including breast cancer, small cell lung cancer (SCLC), prostate cancer, and glioblastoma [148,149,150,151]. This evidence concerns the gene DLL3 and glioblastoma.